← NGNE
NGNE— Neurogene Inc.
MaterialsPharmaceutical Preparations
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue under licensing agreements | $0-100.0% | $925K | $0 | — | — | — | — |
| Research and development expenses | $75.0M+23.1% | $60.9M+37.2% | $44.4M-6.5% | $47.5M | — | — | — |
| General and administrative expenses | $28.3M+25.2% | $22.6M+102.1% | $11.2M+24.2% | $9.0M-58.2% | $21.5M+25.1% | $17.2M-8.6% | $18.8M |
| Total operating expenses | $103.3M+23.7% | $83.5M+50.3% | $55.6M-1.7% | $56.5M | — | — | — |
| Loss from operations | -$103.3M-25.1% | -$82.6M-48.6% | -$55.6M+1.7% | -$56.5M-193.1% | $60.7M+80.0% | $33.7M-52.5% | $71.0M |
| Interest income | $11.5M+36.4% | $8.5M+186.9% | $3.0M+120.7% | $1.3M | — | — | — |
| Interest expense | -$5K+58.3% | -$12K+0.0% | -$12K-500.0% | -$2K | — | — | — |
| Other income | $1.7M+190.1% | $574K-96.5% | $16.4M | — | — | — | — |
| Other expense | -$230K+85.3% | -$1.6M-5500.0% | -$28K-300.0% | -$7K | — | — | — |
| Net loss | -$90.4M-20.2% | -$75.1M-106.9% | -$36.3M+34.2% | -$55.2M+9.1% | -$60.7M-82.4% | -$33.3M+52.1% | -$69.4M |
| Net loss per share, basic (in dollars per share) | -$4K+0.9% | -$4K | — | — | -$1K-71.9% | -$640 | — |
| Net loss per share, diluted (in dollars per share) | -$4K+0.9% | -$4K | — | — | -$1K-71.9% | -$640 | — |
| Weighted-average shares of common stock outstanding, basic (in shares) | $21.33B+21.4% | $17.57B | — | — | $55.04B+6.2% | $51.83B | — |
| Weighted-average shares of common stock outstanding, diluted (in shares) | $21.33B+21.4% | $17.57B | — | — | $55.04B+6.2% | $51.83B | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.